CNBX Pharmaceuticals Inc. (CNBX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Gabriel Yariv
|
President, COO & Executive Chairman | -- | -- | 1976 |
|
Mr. Eyal Barad
|
Co-Founder, CEO & Director | 45.92k | -- | 1965 |
|
Dr. Sigalit Ariely-Portnoy Ph.D.
|
Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board | -- | -- | 1964 |
|
Dr. Tal Mofkadi Ph.D.
|
Financial Advisor & Member of Advisory Board | -- | -- | -- |
|
Mr. Yasha Borstein
|
Chief Data Officer | -- | -- | 1963 |
|
Dr. Yaakov Waksman
|
Head of Cannabidiol Research | -- | -- | 1952 |
|
Dr. Ilya Reznik M.D.
|
Head of Neuropsychiatry Development | -- | -- | -- |
|
Dr. Lior Eshdat
|
Member of Scientific Advisory Board & VP of IP | -- | -- | -- |
CNBX Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1
Description
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
